Desmoplastic melanoma: a brief review and the efficacy of immunotherapy

Click to increase image sizeClick to decrease image size

Declaration of interest

RW Joseph is in the advisory/consulting boards for Bristol-Myers Squibb, Merck, Exelixis, Incyte and Novartis. He has performed clinical trials with Bristol-Myers Squibb, Merck, Roche, Amgen, X4P and Syndax. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.